Corporate ActionAug 10, 2026, 05:34 PM
Curis to Offer Stock & Warrants; Max $13.6M Proceeds
AI Summary
Curis Inc. filed an S-1 registration statement for a best-efforts public offering of up to 3,731,344 shares of common stock and an equal number of warrants, with estimated net proceeds of $13.6 million. The company reported a Q1 2026 net loss of $24.2 million and used $9.0 million in operations, raising substantial doubt about its ability to continue as a going concern beyond 12 months. Proceeds are intended for R&D and general corporate purposes, while clinical trials for emavusertib continue, showing positive preliminary data in PCNSL.
Key Highlights
- Offering up to 3,731,344 shares of common stock and 3,731,344 warrants.
- Assumed combined public offering price of $4.02 per share and warrant.
- Estimated net proceeds of approximately $13.6 million from the offering.
- Substantial doubt about ability to continue as a going concern.
- Q1 2026 net loss of $24.2 million; $9.0 million cash used in operations.
- Current cash not expected to fund operations beyond 12 months.
- TakeAim Lymphoma study showed 100% ORR in 5 BTKi-naïve PCNSL patients.
- Effected a 1-for-20 reverse stock split on July 2, 2026.
Price Impact
More from CRIS